1-3 of 3
Elizabeth Kumm, MS
Close
Sort by
Journal Articles

A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)

Andrew Belch, MD, Atul Sharma, MD, Andrew Spencer, MD, Stefano Tarantolo, Nizar J Bahlis, MD, Dinesh Doval, MD, Gilles Gallant, BPharm, PhD, Elizabeth Kumm, MS, Jerry Klein, PhD, Asher A. Chanan-Khan
Journal: Blood
Blood (2010) 116 (21): 5031.
https://doi.org/10.1182/blood.V116.21.5031.5031
Published: 2010
Journal Articles

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Anas Younes, MD, Julie M. Vose, MD, Andrew D. Zelenetz, MD, PhD, Mitchell R. Smith, MD, PhD, Howard Burris, MD, Stephen Ansell, MD, PhD, Jerry Klein, PhD, Elizabeth Kumm, MS, Myron Czuczman, MD
Journal: Blood
Blood (2005) 106 (11): 489.
https://doi.org/10.1182/blood.V106.11.489.489
Published: 2005
Journal Articles

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Ian W. Flinn, MD, PhD, Elizabeth Kumm, MS, Michael R. Grever, MD, Donna Neuberg, ScD, Gordon W. Dewald, PhD, John M. Bennett, MD, Elisabeth M. Paietta, PhD, Mohamad A. Hussein, MD, Dennis F. Moore, Jr., MD, Martin S. Tallman, MD
Journal: Blood
Blood (2004) 104 (11): 475.
https://doi.org/10.1182/blood.V104.11.475.475
Published: 2004